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Polychlorinated biphenyls (PCBs) were
widely used in a variety of industrial and con-
sumer products before their production was
banned in the United States in the 1970s.
More than 1 million tons of PCBs have been
produced (1) and more than than 70% of the
PCBs made are still in use (2). The chemical
properties that made PCBs desirable in
industrial applications (inflammability,
chemical stability, and miscibility with
organic compounds, or lipophilicity) are the
same properties that have contributed to
their environmental problems. Once in the
environment, stable PCBs degrade slowly
and undergo cycling and transport and are
thus ubiquitous environmental contami-
nants. They are frequently found as complex
mixtures of congeners in soil and dust and on
surfaces in homes and factories. Of the 209
possible PCB congeners, only around 130 are
detectable in commercial mixtures, and far
fewer are found in the environment (3–6).
PCB mixtures induce a variety of bio-
chemical and toxic responses in humans and
animals (4). Many of these effects resemble
those caused by 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) and related halogenated
aromatic hydrocarbons that act through the
aryl hydrocarbon receptor (AhR) signal trans-
duction pathway (7). Dioxin-like PCBs prin-
cipally include the coplanar PCBs such as
IUPAC 77, 81, 126, 169. Dioxin-like effects
include weight loss, thymic atrophy, enzyme
induction, immunotoxicity, teratogenicity,
dermatologic effects, carcinogenicity, and
endocrine disruption (4). The mono-ortho
coplanar PCBs such as 105, 114, 118, 123,
156, 157, 167, 189 have both dioxin-like
effects via the AhR and other mechanisms of
action, such as a phenobarbital-like spectrum
of enzyme induction. Ortho-substituted
PCBs, those that do not bind to the AhR,
elicit a different pattern of toxicity. For
example, ortho-substituted nonplanar PCB
congeners elicit enzyme induction, neurotox-
icity, carcinogenicity, and endocrine disrup-
tion (7–9). Exposure to complex mixtures of
polychlorinated dibenzofurans (PCDFs) and
PCBs have been linked to developmental and
cognitive dysfunctions seen in children born
to mothers who consumed PCDF- and PCB-
contaminated rice oil in Japan (Yusho) and
Taiwan (Yu-Cheng) (10). Reduced levels of
thyroid hormones are detected after develop-
mental exposure to TCDD, non-ortho,
mono- and di-ortho chlorinated PCB con-
geners as well as after exposure to technical
mixtures of PCBs (9,11). 
Oxidative stress involves a depletion of
the protective antioxidant defenses of the
body. Oxidative stress from TCDD expo-
sure causes increased production of reactive
oxygen species, enhanced lipid peroxidation,
decreased glutathione content, decreased
hepatic membrane ﬂuidity, and DNA dam-
age (12,13). Persistent organohalogen com-
pounds are tumor promoters (14), and there
is evidence that this promotion is mediated
at least in part by reactive oxygen species
such as superoxide or hydrogen peroxide
(15). The mechanism by which this effect
occurs remains to be elucidated, but it
appears to be AhR mediated (13). Markers of
oxidative stress were evaluated because PCBs
and dioxins induce oxidative stress (16),
which has been implicated in the promotion
of cancer (17) and developmental toxicity
(12); thus, it is important to evaluate both
dioxin-like and non–dioxin-like PCBs for
similar activity. In the Aroclor mixtures there
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Articles
Aroclor 1254 is a commercial mixture of polychlorinated biphenyls (PCBs), which is deﬁned as
being 54% chlorine by weight. However, the congener composition varies from lot to lot. Two
lots which have been used in toxicity studies, 124-191 and 6024 (AccuStandard), were analyzed
for their congener composition. Lot 6024 has approximately 10 times the dioxin toxic equivalents
(TEQ) of lot 124-191. The purpose of this study was to determine if the difference in the TEQ of
the two lots explains the different in vivo responses seen on a weight basis. Male Long-Evans rats
(70 days old) were treated orally with a single dose of 0–1,000 mg/kg of each lot. Hepatic
ethoxy-, methoxy-, and pentoxyresorufin O-deethylase (EROD, MROD, and PROD, respec-
tively) activities as well as serum thyroxine (T4) concentrations and measures of oxidative stress
were determined 4 days after treatment. Results, on a weight basis, indicate that lot 6024 led to a
greater induction of EROD, MROD, and PROD but not total T4 reduction. The differences in
TEQ between the lots explained the differential induction of EROD and MROD but did not
account for the induction of PROD nor decreases in T4. PROD induction is not due to dioxin-
like congeners, whereas the decrease in serum T4 levels may involve multiple mechanisms. Effects
on the antioxidants ascorbic acid and uric acid were seen only at the highest mass dose for both
lots and were not explained by the difference in TEQ. These results illustrate that the differences
in the TEQ explain the differences in the strict dioxin-like effects (EROD, MROD induction),
but the non–dioxin-like congeners cause other effects that are not associated with the aryl hydro-
carbon receptor (e.g., PROD). In addition, supra-additive effects also occur in the mixture (T4,
oxidative stress). Thus, current results demonstrate that overall toxicity cannot be predicted on
the basis of the TEQ values. It is also critical that the lot number is reported in studies conducted
with Aroclor 1254 because the congener composition and therefore the effects observed can be
very different. Key words: Aroclor 1254, dioxin, hepatic enzymes, oxidative stress, polychlorinated
biphenyls, thryroid hormones, toxic equivalents. Environ Health Perspect 109:1163–1168 (2001).
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http://ehpnet1.niehs.nih.gov/docs/2001/109p1163-1168burgin/abstract.htmlare both dioxin-like and non–dioxin-like PCB
congeners so measures of oxidative stress were
used to evaluate biochemical and toxic effects.
2,3,7,8-TCDD is never found alone in
the environment, but rather as a component
of a complex mixture of compounds, many of
which share a common AhR-mediated mech-
anism of action and which elicit similar bio-
logical responses. Because of this, a relative
potency-ranking scheme was created for haz-
ard and risk assessment of complex mixtures
of dioxin-like compounds, including the
coplanar and mono-ortho PCBs (1,2,4,18).
The toxic equivalency factor (TEF) approach
assigns a relative potency value to polyhalo-
genated aromatic hydrocarbons based on
four criteria, one of which is the mechanism
of action via the AhR [see Van den Berg (1)
for discussion of the criteria]. TCDD is the
most potent of the structurally related poly-
halogenated aromatic hydrocarbons and thus
has a TEF of 1. The TCDD toxic equiva-
lence (TEQ) of a mixture is determined from
the assigned TEF and the concentrations of
the given individual congeners, as shown in
the following equation:
TEQ = Σ [(congeneri × TEFi)n],
where n is the number of congeners.
The TEQ approach works well when
only PCDDs, PCDFs, and dioxin-like PCBs
are present. For example, the induction of
cleft palate in mice follows a strictly dose-
additive pattern (19), as does immunotoxic-
ity (20). Recent studies have shown that
decreases in hepatic retinoid levels, especially
retinyl palmitate, also behave in a strictly
additive manner (21). However, when
non–dioxin-like PCBs are present, applica-
tion of the TEF approach must be used with
caution. Results from laboratory animal and
wildlife studies suggest the predictive value of
TEFs for PCBs may be both species and
response dependent (5). This is due to both
synergistic and antagonistic interactions that
have been observed with PCB mixtures. In
the case of an antagonist, the TEF approach
would overestimate the toxicity of a PCB
mixture. For example, Smialowicz et al. (20)
found that cotreatment with TCDD (1 µg
TCDD/kg) and PCB 153 (358 mg/kg)
resulted in no change in the plaque-forming
cell response relative to corn oil, but treat-
ment with TCDD alone led to significant
suppression and treatment with PCB 153
alone led to enhancement of the plaque-
forming cell response. More important, and
of greater concern for the protection of
human health and the environment, is that
the TEF approach could signiﬁcantly under-
estimate the toxicity of a mixture if synergism
is occurring, as demonstrated in the induc-
tion of hepatic porphyrins (22). Current
approaches focus on the toxicity of individual
congeners, assuming additivity, and do not
take into account possible interactions.
Aroclors are complex commercial mix-
tures of PCBs. Aroclor 1254 is defined by
the weight percentage of chlorine, but the
PCB congener composition varies from lot
to lot. Two lots (AccuStandard, New Haven,
CT) that have been used in toxicity studies
and are representative of commercial Aroclor
mixtures, 124-191 and 6024, were analyzed
for their congener composition (23). Lot
6024 had approximately 10 times the TEQ
of lot 124-191 (Table 1). The purpose of
this study was to determine if the difference
in the TEQ for the two lots explained the
different biological responses seen on a
weight basis. To test whether the difference
in TEQ could explain the differential effects
observed, male Long-Evans rats were treated
via oral gavage with graded doses of 0–1,000
mg/kg of each lot (Table 2). Enzymatic
markers of cytochrome P450 1A1 and 1A2
induction, ethoxyresorufin O-deethylase
(EROD) and methoxyresoruﬁn O-deethylase
(MROD), were used as they are AhR-medi-
ated responses and are common to TCDD
and dioxin-like PCBs. Because many of the
non–dioxin-like PCB congeners act in a phe-
nobarbital-like manner (8) and induce
CYP2B, the pentoxyresorufin O-deethylase
(PROD) assay was used to measure this
induction (24). Serum T4 concentrations and
measures of oxidative stress were also deter-
mined, and the degree of response was com-
pared on a mass basis and on a TEQ basis. 
Materials and Methods
Chemicals. Aroclor lots 124-191 and 6024
(99% purity) were obtained from
AccuStandard (New Haven, CT). Ethoxy-
resorufin and pentoxyresorufin were pur-
chased from Sigma (St. Louis, MO).
Methoxyresorufin was purchased from
Molecular Probe (Eugene, OR). Radio-
immunoassay kits for thyroid hormone mea-
surements were purchased from Diagnostic
Products, Inc. (Los Angeles, CA). Other
chemicals were purchased from commercial
sources (Sigma) and were of the highest
grade commercially available.
Animal treatment. Male Long-Evans rats
(Charles River Laboratories, Inc., Raleigh,
NC) were used in order to compare the results
with those obtained previously in experiments
conducted with Aroclor 1254 in this labora-
tory. The animals were obtained at 60 days of
age and acclimatized for 10 days before the
study. They were maintained according to the
National Institutes of Health Guide for the
Care and Use of Laboratory Animals (25) in an
animal facility approved by the Association for
Assessment and Accreditation of Laboratory
Animal Care. Animals were housed individu-
ally in clear polycarbonate cages with pine
shavings (North Eastern Products Inc.,
Warrensburg, NY) and given food (Rodent
Chow; Purina, St. Louis, MO) and tap water
ad libitum. The room was maintained at 21 ±
2°C with 55 ± 5% relative humidity. The
lights were on a 12-hr light:dark cycle with
lights on at 0600 hr. 
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Table 1. Summary of dioxin-like PCB congeners for TEQ comparison.
Lot 124-191 Lot 6024
Concentration Concentration
Congeners (mg/g) TEF TEQ (µg/g) (mg/g) TEF TEQ (µg/g)
Mono-ortho
105 51 0.0001 5.1 130 0.0001 13
118 127 0.0001 12.7 124 0.0001 12.4
123 0.57 0.0001 0.057 2.14 0.0001 0.214
131/114/122 0.05 0.0005 0.025 0.78 0.0005 0.39
156 4.8 0.0005 2.4 51 0.0005 25.5
157 0.36 0.0005 0.18 26.3 0.0005 13.15
Coplanar
77 0.01 0.0001 0.001 27.2 0.0001 2.72
81 0.01 0.0001 0.001 0.28 0.0001 0.028
126 0.167 0.1 16.7 3.24 0.1 324
169 0.013 0.01 0.13 0.022 0.01 0.22
Furans
4 Cl 0.001678 0.1 0.1678 0.001693 0.1 0.1693
5 Cl 0.002933 0.5 1.4665 0.014151 0.5 7.0755
6 Cl 0.004744 0.1 0.4744 0.017191 0.1 1.7191
7 Cl 0.001649 0.01 0.01649 0.004724 0.01 0.04724
8 Cl 0.0000356 0.0001 0.00000356 0.000946 0.0001 0.0000946
Grand total 39.41919356 400.63323
Table 2. Dose schedule for two lots of Aroclor
1254 based on weight and TEQ values.
Dose (µg TEQ/kg)
Dose (mg/kg) Lot 124-191 Lot 6024
00 0
1— 0.4
3— 1.2
10 0.4 4
30 1.2 12
100 4 40
300 12 120
1,000 40 400Each dose group consisted of ﬁve animals,
weighing between 300 and 400 g each. They
were treated via oral gavage with corn oil (2
mL/kg). Dose levels were chosen based on the
results of Nishida et al. (26) because that
experiment was conducted successfully using
the more potent lot 6024. The doses for lot
124-191 were 0, 10, 30, 100, 300, or 1,000
mg/kg body weight, and the doses for lot
6024 were 0, 1, 3, 10, 30, 100, 300, or 1,000
mg/kg body weight. To compare the dose lev-
els on a TEQ basis, two dose groups of 1 and
3 mg/kg of lot 6024 were added, which
equates on a TEQ basis to 10 and 30 mg/kg
of lot 124-191, respectively (Table 2).
Calculated TEQs were based on consensus
TEFs from the World Health Organization
(1) and the congener concentrations present in
the two lots were determined by electron-cap-
ture detection and gas chromatography/mass
spectrometry (Table 1) (23). Three days after
treatment, the animals were euthanized by car-
bon dioxide asphyxiation. We collected
blood (1–2 mL) for serum triiodothyronine
(T3)/T4 analysis; the livers were weighed and
saved for enzyme analysis and determination
of oxidative stress; and thymic weights were
obtained. Organs were snap frozen in liquid
nitrogen and stored at –80°C until analyzed.
Hepatic microsomal suspensions were pre-
pared as previously described (27). 
Enzymatic assays. For cytochrome P450
activity measurements, hepatic microsomes
were appropriately diluted to provide linear-
ity of the reaction with protein concentra-
tion and time. The assay conditions were
previously reported by our laboratory (28).
EROD assay. Cytochrome P450 1A1
enzyme activity was measured using the
EROD activity assay. EROD activity was
determined from the rate of formation of
resorufin from ethoxyresorufin as described
by DeVito (28).
MROD assay. The MROD activity
assay, a measure of the activity of CYP1A2,
was carried out as for EROD except that
methoxyresorufin was used as the substrate
(28).
PROD assay. The PROD activity assay, a
measure of CYP2B activity, was carried out as
for EROD except that pentoxyresoruﬁn was
used as the substrate instead of ethoxyresoruﬁn
as described by van Birgelen et al. (24). 
Circulating thyroid hormones. Blood was
collected and allowed to clot on ice for 1 hr.
Blood samples were centrifuged at 750 × g
for 15 min to separate serum. Serum samples
were stored at –80°C until radioimmunoas-
say as described previously (28). Total T4
and T3 levels were determined with standard
radioimmunoassay kits (Coat-A-Count
Total T3 and Total T4; Diagnostic Products
Corp, Los Angeles, CA) based on competi-
tive protein binding. 
Cytochrome c reduction assay. Production
of superoxide anion by the reduction of
cytochrome c was measured by the method of
Babior et al. (30). Reduced cytochrome c was
collected for spectrophotometric measure-
ment on a Novaspec II spectrophotometer
(Pharmacia Biotech, Cambridge, England).
Although this is not an entirely specific
method because other intracellular substances
also reduce cytochrome c, it has been used to
estimate super oxide anion production (31). A
10% (w/v) tissue homogenate was prepared in
Tris-KCl buffer (0.05 M Tris and 1.15% w/v
KCl, pH 7.4). Each sample for analysis con-
tained 2 mL phosphate-buffered saline (pH
7.2), 45 nmol cytochrome c, and 20 µL tissue
homogenate. Absorbance was determined at
550 nm and converted to nanomoles of
cytochrome c reduced per minute, using an
extinction coefﬁcient of 2.1 × 104/M/cm.
Determination of ascorbic acid and uric
acid. Ascorbic acid and uric acid concentra-
tions were determined as described by Ghio
et al. (32). Between 50 and 100 mg of tissue
was homogenized and acidiﬁed with 3 mL of
60% perchloric acid and centrifuged at
20,000 × g for 30 min at 4° C. Using HPLC
(Waters RCM; Millipore Corporation,
Marlborough, MA) with electrochemical
detection (BAS model LC-4B; Bioanalytical
Systems, West Lafayette, IN), the super-
natant was assayed for ascorbate and urate.
Total glutathione. Total glutathione
(GSH) was determined by a modiﬁcation of
the DTNB-GSSG reductase recycling assay
previously described by Anderson (33). This
assay was modified for use on the COBAS
FARA II (Hoffman-La Roche, Branchbury,
NJ) centrifugal spectrophotometer.
Protein concentration assay. Microsomal
protein concentrations were determined
according to the method of Bradford (34)
using a Bio-Rad (Richmond, CA) micropro-
tein assay kit with bovine serum albumin as
the standard. Protein concentrations from
GSH and ascorbic acid/uric acid samples
were determined using Pierce Commassie
Plus Protein assay reagent (Pierce, Rockford,
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Figure 1. Comparison of EROD enzymatic activity based on (A) weight and (B) TEQ. On a weight basis, lot
6024 induces higher EROD activity than lot 124-191, as predicted based on mono-ortho and TCDD-like PCB
congener composition. On a TEQ basis, lot 6024 has similar induction to lot 124-191, but at a lower dose level. 
*Statistically significant difference from control group (p < 0.05); **Statistically significant difference from other lot at
same dose (p < 0.05); n = 5.
Figure 2. Comparison of MROD enzymatic activity based on (A) weight and (B) TEQ. On a weight basis, lot
6024 induces higher MROD activity than lot 124-191, as predicted based on mono-ortho and TCDD-like
PCB congener composition. On a TEQ basis, lot 6024 has similar induction to lot 124-191, but this occurs a
lower dose level. 
*Statistically significant difference from control group (p<0.05) **Statistically significant difference from other lot at
same dose (p<0.05); n = 5.
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**IL) (32). Sample protein concentration was
determined from a standard curve using
bovine serum albumin standards.
Statistical analysis. Data are presented as
means ± standard deviations. Intergroup com-
parisons were performed by a two-factor
analysis of variance with a Bonferroni correc-
tion to the p-value to control for experimental
error. Differences between groups were con-
sidered statistically signiﬁcant when p < 0.05.
Results 
Both lots demonstrated increased EROD
activity on a weight basis. Lot 6024 showed
a significantly greater dose-dependent
increase over lot 124-191 (Figure 1A). On a
TEQ basis, both lots induced a similar level
of activity (Figure 1B).
On a weight basis, lot 6024 induced sig-
nificantly greater MROD activity than lot
124-191 (Figure 2A). On a TEQ basis, both
lots induced a similar level of activity (Figure
2B).
On a weight basis, lot 6024 induced sig-
nificantly greater PROD activity than lot
124-191 (Figure 3A). However, when com-
pared on an equivalent TEQ basis, lot
124-191 was a more potent inducer of
PROD (Figure 3B) than was lot 6024.
On a weight basis, the two PCB mixtures
resulted in the same dose–response curve for
the decrease in total T4 (Figure 4A), and there
were no consistent dose–response ﬁndings for
T3 (data not shown). When compared on the
basis of TEQ, lot 124-191 was more potent
for the decrease in total T4 (Figure 4B).
Effects on cytochrome c reduction, a
measure of superoxide anion production,
were not seen for either lot (data not shown).
There were no consistent dose–response ﬁnd-
ings for GSH (data not shown). Ascorbic
acid levels increased only at the highest mass
of both mixtures, with a greater effect caused
by lot 6024 (Figure 5). When compared on a
TEQ basis, there is no effect seen on lot
6024 when at the same TEQ as lot 124-191,
but at a 10 times lower mass. Uric acid
showed a signiﬁcant decrease from control at
the highest dose level for both lots (Figure 6).
On a weight basis, lot 6024 showed a greater
decrease than lot 124-191 (Figure 6A). On
an equivalent TEQ basis, lot 124-191 shows
a greater decrease in uric acid levels than lot
6024 (Figure 6B).
Discussion
The purpose of this study was to determine if
the difference in the TEQ for the two
Aroclor lots 6024 and 124-191 explained the
different magnitude of biological responses
seen on a weight basis. We found that the
differences in TEQ were able to explain
induction levels of EROD and MROD. The
higher amount of dioxin-like PCBs present
in lot 6024 gave rise to greater enzyme
induction as measured by EROD and
MROD. However, the PROD effects were
not due to dioxin-like congeners and thus
could not be predicted by the TEQ. 
Enzymatic markers of cytochrome P450
1A1 and 1A2 induction were used because
they are AhR-mediated responses and are
common to TCDD and dioxin-like PCBs.
Because many of the non–dioxin-like PCB
congeners act in a phenobarbital-like man-
ner (8) and induce CYP2B, the PROD assay
was used to measure this induction (24).
PCB 153 has been shown to increase PROD
induction (35), but both lots 124-191 and
6024 have comparable amounts [31.8 mg/g
and 33.93 mg/g, respectively (23)]. PCB
126, on the other hand, causes a marked
induction of CYP1A2 activity (36). Lot
6024 has several times more PCB126 than
lot 124-191. The greater effect on PROD by
lot 6024, which also had a higher TEQ, may
be due to the excess of congeners 105, 138,
156, and 157 as compared with lot 124-191
(Table 1) (23). These congeners have pheno-
barbital-like induction activity.
The decrease in T4 is likely due to multi-
ple mechanisms such as induction of several
uridine diphosphate glucuronysyltransferases
(UDPGTs) and binding to T4 transport pro-
tein, transthyretin (TTR) (11,37). Cheek et
al. (11) found that hydroxylated PCBs are
potent ligands for TTR, having afﬁnities in
the 1 nM range, 50-fold greater than that of
T4. Recently, Chauhan et al. (37) studied
the structure–activity relationships of 49
PCB congeners and demonstrated differen-
tial binding activity on T4–TTR binding.
When compared on the basis of TEQ, the
greater mass of PCB congeners in lot
124-191 was more effective for the decrease
in total T4 (Figure 4B). Thus, TEQ alone is
not predictive of the decrease in T4. 
PCBs are known to be developmental
toxicants at environmentally relevant con-
centrations (38). Abnormalities associated
with low-level PCB exposure in humans
include hypoactivity and impaired learning
Articles • Burgin et al.
1166 VOLUME 109 | NUMBER 11 | November 2001 • Environmental Health Perspectives
Figure 3. Comparison of PROD enzymatic activity based on (A) weight and (B) TEQ. On a weight basis, lot
6024 induces higher PROD activity than lot 124-191, as predicted based on non-ortho congener composi-
tion. However, on a TEQ basis, lot 124-191 was more potent for PROD than was lot 6024. 
*Statistically significant difference from control group (p<0.05). **Statistically significant difference from other lot at
same dose (p<0.05); n =5 .
Figure 4. Comparison of total T4 activity based on (A) weight and (B) TEQ. The two PCB mixtures resulted
in the same dose–response curve for the decrease in total T4 on a weight basis (A), and there were no
consistent dose–response findings for T3 (data not shown). When compared on the basis of TEQ, lot
124-191 was more potent for the decrease in total T4 (B). 
*Statistically signiﬁcant difference from control group (p < 0.05); n = 5. 
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* *(9,39,40). In the Netherlands, PCB levels in
women were inversely related to serum total
T4 in their newborn children, as well as birth
size and early growth rate (40). Some con-
geners, especially the non-ortho substituted
congeners such as PCB 126, are particularly
potent at reducing circulating T4 levels, but
they do not become concentrated in brain
tissue. In contrast, some ortho-substituted
congeners such as PCB 153 appear to con-
centrate in brain tissues and may bind to the
thyroid receptor but are not as potent at
reducing circulating T4 levels (9).
No effects of acute PCB exposure were
seen for GSH. This may be surprising at ﬁrst
because GSH plays a fundamental role in the
antioxidant biology of mammals. Severe
GSH depletion has been associated with such
pathological consequences as susceptibility to
the development of lipid peroxidation. It
plays a role in the regeneration of ascorbic
acid (vitamin C) and reduction of the oxi-
dized form of tocopherol (vitamin E) (16). In
this study, the animals were terminated at
day 4, which may be enough time for the
GSH pools in the body to be replenished.
During a subchronic study, it would be rea-
sonable to expect GSH depletion as a conse-
quence of TCDD exposure as observed by
Slezak et al. (16).
Recent studies indicate that production
of reactive oxygen species after TCDD expo-
sure is not solely dependent on TCDD con-
centration in the tissue. Although acute,
low-dose exposure to TCDD does not
appear to cause oxidative stress, very low
doses of TCDD that result in tissue concen-
trations similar to human background levels
produced an effect on an oxidative stress
endogenous defense system (16). Previous
studies demonstrate that oxidative stress is
seen only after high-dose, acute exposure to
TCDD (12,16). A dose of 1,000 mg/kg of
lot 124-191 results in a dose of about 800
mg/kg of non–dioxin-like PCBs. However,
non–dioxin-like PCBs can also induce oxida-
tive stress (41). This suggests that there are
multiple mechanisms which lead to a greater
than additive effect of the individual con-
geners resulting in higher than expected levels
of oxidative stress as measured by glutathione,
ascorbic acid, and uric acid, markers of
antioxidant defense. The presence of oxidative
stress at the highest mass is likely due to
non–dioxin-like PCBs or to interactions.
It is apparent that the contrast in the
TEQ explains the variances in the dioxin-
like effects, but the non–dioxin-like con-
geners cause other responses that are not
associated with the AhR. Use of TEFs
assumes that polyhalogenated aromatic
hydrocarbon congeners act in an additive
manner. Assumption of additivity is only
valid if the dioxin-like chemical has no
mechanism of action other than binding to
the AhR and the induction of response by
different chemicals occurs by the same
mechanism of action. This appears to hold
true for all of the laterally substituted poly-
halogenated dibenzo-p-dioxins and PCDFs,
and the coplanar PCBs, especially PCB 126.
It is not true with the mixed-inducer PCBs
(i.e., the mono-ortho substituted congeners
such as PCBs 105, 118, and 156). 
However, when non–dioxin-like PCBs
are present, application of the TEF approach
must be used with caution. The potential
exists for synergistic and antagonistic interac-
tions, which have been observed with PCB
mixtures, although these potentials have not
been fully explored. In the case of synergism,
the congeners act via multiple mechanisms
to produce a greater than additive effect
which the TEQ would thus underpredict.
Van Birgelen et al. (42) found clear evidence
of synergism for increases in both hepatic
and urinary porphyrins as well as signiﬁcant
decreases in total T4 (36,43).
In the case of antagonism, the congeners
would work against each other to cause a less
than additive effect that the TEQ would
then overpredict. For example, Morrissey et
al. (44) found that combinations of
2,2´,4,4´,5,5´-hexachlorobiphenyl (PCB-153;
125–500 mg/kg) and TCDD (15 µg/kg)
decreased the incidence of cleft palate in
C57BL/6N mice induced by TCDD alone.
Antagonism of hydronephrosis also occurred
in this study (500 mg PCB-153/kg and 15
µg/kg TCDD). It is believed that these
examples of nonadditivity are due to multi-
ple mechanisms of action that can result in a
common phenotype.
Kodavanti et al. (23) described the in
vitro effects of Aroclor 1254 on neurochemi-
cal end points, in particular protein kinase C
(PKC) translocation and intracellular Ca2+
buffering. Lot 124-191 was more potent in
PKC translocation than lot 6024, whereas lot
6024 was slightly more active on Ca2+ buffer-
ings than lot 124-191 on a mass basis. The
difference in results for PKC translocation
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Figure 5. Comparison of ascorbic acid (AA) levels based on (A) weight and (B) TEQ. AA levels increased only
at the highest mass of both mixtures, with a greater effect caused by lot 6024. When compared on a TEQ
basis, there is no effect seen on lot 6024 when at the same TEQ as lot 124-191, but at a 10 times lower mass. 
*Statistically signiﬁcant difference from control group (p < 0.05); n = 5. 
11,000
10,000
9,000
8,000
7,000
6,000
5,000
4,000
01 10 100 1,000
Dose (mg/kg)
n
g
 
A
A
/
m
g
 
p
r
o
t
e
i
n
A B
01 1 0 100
Dose (µgTEQ/kg)
*
* *
Lot 124-191
Lot 6024
* 11,000
10,000
9,000
8,000
7,000
6,000
5,000
4,000
n
g
 
A
A
/
m
g
 
p
r
o
t
e
i
n
1,000
Figure 6. Comparison of uric acid (UA) levels based on (A) weight and (B) TEQ. Uric acid showed a signiﬁ-
cant decrease from control at the highest dose level for both lots. On a weight basis, lot 6024 showed a
greater decrease than lot 124-191 at the same dose level (A). On an equivalent TEQ basis, lot 124-191
shows a greater decrease in uric acid levels than lot 6024 (B). 
Statistically signiﬁcant difference from control group (p < 0.05); n = 5. 
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*and intracellular Ca2+ buffering could not be
attributed to the non-ortho congeners or
PCDFs, as they are inactive in these assays
(23). These outcomes could not be predicted
by the TEQ, which indicates there are
non–dioxin-like congeners present in higher
amounts in lot 124-191 driving this
response. Analysis of the two lots revealed
that PCBs 44, 49, 52, 66, 85, 97, 132, 135,
137/176, 149, 174, and 187 were higher in
lot 124-191, and PCBs 40, 47-48, 70, 74,
77, 81, 92, 99, 105, 110, 123, 126, 138,
156, and 157 were higher in lot 6024. 
For protection of human health and the
environment, current regulations rely on the
toxicity of complex mixtures and do not
take into account possible interactions.
TEFs were developed to facilitate the esti-
mation of the toxicity of these complex
mixtures, but this assumes that the
dose–response curves are parallel for a given
response between chemicals and that com-
bined effects are additive. Overall toxicity of
complex mixtures cannot be entirely pre-
dicted based on the TEQ values, and in the
future it is vital that the lot number in stud-
ies conducted with Aroclor 1254, as well as
the congener composition of the mixture,
are reported. It is important for researchers
to be aware that differences exist from lot to
lot of Aroclor in terms of biochemical and
toxic responses. Laboratory results may not
predict environmental impact when the con-
gener compositions deviate. Clearly, depict-
ing environmental or biological samples as
resembling Aroclor mixtures does not ade-
quately account for effects because congener
composition varies.
TEQ determines the amount of dioxin-
like activity in a mixture. However, because
only a small portion of the total mass of
PCB mixtures are coplanar non-ortho con-
geners that elicit dioxin-like activities, the
TEF approach based on AhR-mediated
responses cannot be applied for the risk
assessment of non–AhR-mediated toxic
effects (7). For a complete evaluation of risks
due to PCBs exposure, consideration of the
effects of both ortho- and non-ortho substi-
tuted congeners is also required.
REFERENCES AND NOTES
1. Van den Berg M, Birnbaum L, Bosveld A, Brunström B,
Cook P, Feeley M, Giesy J, Hanberg A, Hasegawa R,
Kennedy SW, et al. Toxic equivalency factors (TEFs) for
PCBs, PCDDs, PCDFs for humans and wildlife. Environ
Health Perspect 106:775–792 (1998).
2. Birnbaum LS. TEFs: a practical approach to a real-world
problem. Hum Ecol Risk Assess 5(1):13–24 (1999).
3. Erickson MD. Analytical Chemistry of PCBs. Boston:
Butterworth Publishers, 1986. 
4. Safe S. Polychlorinated biphenyls (PCBs): environmental
impact, biochemical and toxic responses, and implica-
tions for risk assessment. Crit Rev Toxicol 24:87–149.
5. McFarland VA, Clark JU. Environmental occurrence,
abundance, and potential toxicity of polychlorinated
biphenyl congeners: considerations for a congener-spe-
ciﬁc analysis. Environ Health Perspect 81:225–239 (1989). 
6. Giesy JP, Kannan K. Dioxin-like and non-dioxin-like toxic
effects of polychlorinated biphenyls (PCBs): implications
for risk assessment. Crit Rev Toxicol 28(6):511–569 (1998).
7. Birnbaum LS. Evidence for the role of the Ah receptor in
response to dioxin. Prog Clin Biol Res 387:139–154 (1994).
8. Tilson HA, Kodavanti PRS. The neurotoxicity of polychlori-
nated biphenyls. Neurotoxicology 19(4-5):517–526 (1998).
9. Zoeller RT, Dowling ALS, Vas AA. Developmental expo-
sure to polychlorinated biphenyls exerts thyroid hormone-
like effects on the expression of RC3/neurogranin and
myelin basic protein messenger ribonucleic acids in the
developing rat brain. Endocrinology 141:181–189 (2000).
10. Kuratsune M, Yoshimura H, Hori Y, Okumura M, Masuda
Y. Yusho: A Human Disaster Caused by PCBs and
Related Compounds. Fukuoka, Japan:Kyushu University
Press, 1996. 
11. Cheek AO, Kow K, Chen J, McLachlan JA. Potential
mechanisms of thyroid disruption in humans: interaction
of organochlorine compounds with thyroid receptor,
transthyretin, and thyroid-binding globulin. Environ
Health Perspect 107:273–278 (1999).
12. Stohs S. Oxidative stress induced by 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). Free Radic Biol Med
9(1):79–90 (1990).
13. Alsharif NZ, Schlueter WJ, Stohs SJ. Stimulation of
NADPH-dependent reactive oxygen species formation
and DNA damage by 2,3,7,8-tetrachlorodibenzo-p-dioxin
in rat peritoneal lavage cells. Arch Environ Contam
Toxicol 26:392–397 (1994).
14. Cogliano VJ. Assessing the cancer risk from Environmental
PCBs. Environ Health Perspect 106:317–323 (1998). 
15. Brown J, Fish K, Silkworth J, Mayes B. A Proposed
mechanism for rodent liver carcinogenesis by persistent
organohalogen compounds at the maximum tolerated
dose. Organohalogen Compounds 37:67–70 (1998).
16. Slezak B, Hatch G, DeVito M, Diliberto J, Slade R,
Crissman K, Birnbaum L. Oxidative stress in female
B6C3F1 mice following acute and subchronic exposure
to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Sci
54(2):390–398 (2000).
17. Tritscher A, Clark G, Sewall C, Sills R, Maronpot R, Lucier
G. Persistence of TCDD-induced hepatic cell prolifera-
tion and growth of enzyme altered foci after chronic
exposure followed by cessation of treatment in DEN initi-
ated female rats. Carcinogenesis 16(11):2807–2811 (1995).
18. Birnbaum LS, DeVito MJ. Use of toxic equivalency factors
for risk assessment for dioxin and related compounds.
Toxicology 105:391–401 (1995).
19. Birnbaum LS. Developmental toxicity of TCDD and related
compounds: species sensitivities and differences. In:
Biological Basis for Risk Assessment of Dioxins and
Related Compounds (Gallo MA, Scheuplein RJ, van
Heijden KA, eds). Plainview, NY:Cold Spring Harbor
Laboratory Press, 1991;51–67.
20. Smialowicz RJ, DeVito MJ, Riddle MM, Williams WC,
Birnbaum LS. Opposite effects of 2,2’,4,4’,5,5’-hexachlor-
biphenyl and 2,3,7,8-tetrachlorodibenzo-p-dioxin on the
antibody response to sheep erthrocytes in mice. Fundam
Appl Toxicol 37:141–149 (1997).
21. Ross DG, van Birgelen A, DeVito MJ, Birnbaum LS.
Relative potency factors derived from CYP1A induction
in mice are predictive for alterations in retinoid concen-
trations after subchronic exposure to mixtures of PCDDs,
PCDFs, and PCBs in female Sprague-Dawley rats.
Organohalogen Compounds 34:281–285 (1997).
22. van Birgelen APJM, Fase KM, van der Kolk J, Poiger H,
Brouwer A, Seinem W, van den Berg M. Synergistic
effect of 2,2’,4,4’,5,5’-hexachlorobiphenyl and 2,3,7,8-
tetrachlordibenzo-p-dioxin on hepatic porphyrin levels in
the rat. Environ Health Perspect 104:550–557 (1996).
23. Kodavanti PRS, Kannan N, Yamashita N, Derr-Yellin EC,
Ward TR, Burgin DE, Tilson HA, Birnbaum LS. Differential
effects of two lots of Aroclor 1254: congener-specific
analysis and neurochemical end points. Environ Health
Perspect 109:1153–1161 (2001)
24. van Birgelen APJM, Ross DG, DeVito MJ, Birnbaum LS.
Interactive effects between 2,3,7,8-tetrachlorodibenzo-p-
dioxin and 2,2’,4,4’,5,5’-hexachlorobiphenyl in female
B6C3F1 mice: tissue distribution and tissue-specific
enzyme induction. Fundam Appl Toxicol 34:118–131 (1996).
25. Institute of Laboratory Animal Resources. Guide for the
Care and Use of Laboratory Animals. Washington,
DC:National Academy Press, 1996. 
26. Nishida N, Farmer JD, Kodavanti PR, Tilson HA, MacPhail
RC. Effects of acute and repeated exposures to Aroclor
1254 in adult rats: motor activity and ﬂavor aversion con-
ditioning. Fundam Appl Toxicol 40:68–74 (1997). 
27. DeVito MJ, Ma X, Babish J, Menache M, Birnbaum L.
Dose-response relationships in mice following subchronic
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin: CYP1A1,
CYP1A2, estrogen receptor and protein tyrosine phospho-
rylation. Toxicol Appl Pharmacol 124:82–90 (1994).
28. DeVito MJ. Comparative ability of various PCBs, PCDFs,
and TCDD to induce cytochrome P450 1A1 and 1A2 activ-
ity following 4 weeks of treatment. Fundam Appl Toxicol
20:125–130 (1993).
29. Kodavanti PRS, Derr-Yellin EC, Mundy WR, Shafer TJ,
Herr DW, Barone S, Choksi NY, MacPhail RC, Tilson HA.
Repeated exposure of adult rats to Aroclor 1254 causes
brain region-speciﬁc changes in intracellular Ca2+ buffer-
ing and protein kinase C activity in the absence of
changes in tyrosine hydroxylase. Toxicol Appl Pharmacol
153:186–198 (1998).
30. Babior BM, Kipner RS, Cerutte JT. Biological defense
mechanisms. The production by leukocytes of superoxide,
a potential bactericidal agent. J Clin Invest 52:741–744
(1973).
31. Hassoun E, Wilt S, DeVito M, van Birgelen A, Alsharif N,
Birnbaum L, Stohs S. Induction of oxidative stress in brain
tissues of mice after subchronic exposure to 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. Toxicol Sci 42:23–27 (1998).
32. Ghio A, Kennedy T, Crissman K, Richards J, Hatch G.
Depletion of iron and ascorbate in rodents diminishes
lung injury after silica. Exp Lung Res 24(2):219–232 (1998).
33. Anderson ME. Determination of glutathione and glu-
tathione disulfide in bIological samples. Methods
Enzymol 113:548–555 (1985).
34. Bradford MM. A rapid and sensitive method for quantita-
tion of microgram quantities of protein utilizing the princi-
pal of protein-dye binding. Anal Biochem 72:248–252 (1976).
35. van der Kolk J, van Birgelen APJM, Poiger H, Schlatter
C. Interactions of 2,2’,4,4’,5,5’-hexachlorobiphenyl and
2,3,7,8-tetrachlorodibenzo-p-dioxin in a subchronic feed-
ing study in the rat. Chemosphere 25(12):2023–2027
(1992). 
36. van Birgelen AP, van der Kolk J, Fase KM, Bol I, Poiger H,
Brouwer A, van den Berg M. Toxic potency of 3,3’,4,4’,5-
pentachlorobiphenyl relative to and in combination with
2,3,7,8-tetrachlorodibenzo-p-dioxin in a subchronic feeding
study in the rat. Toxicol Appl Pharmacol 127:209–221 (1994). 
37. Chauhan KR, Kodavanti PRS, McKinney JD. Assessing
the role of ortho-substitution on polychlorinated biphenyl
binding to transthyretin, a thyroxine transport protein.
Toxicol Appl Pharmacol 162:10–21 (2000).
38. Gladen BC, Rogan W. Effects of perinatal polychlori-
nated biphenyls and dichlorophenyl dichloroethene on
later development. J Pediatr 119:58–63 (1991).
39. Jacobsen JL, Jacobsen SW. Evidence for PCBs as neu-
rodevelopmental toxicants in humans. Neurotoxicology
18(2):415–424 (1997).
40. Patandin S, Lanting CI, Mulder PGH, Boersma R, Sauer
PJJ, Weisglas-Kuperus N. Effects of environmental
exposure to polychlorinated biphenyls and dioxins on
cognitive abilities in Dutch children at 42 months of age.
J Pediatr 134:33–41 (1999).
41. Fish KM, Silkworth JB, Brown JF. Enzymatic bases for
tumorigenic oxidant production in the livers of rats chron-
ically dosed with PCBs. Organohalogen Compounds
37:113–116 (1998).
42. van Birgelen APJM, DeVito MJ, Akins JM, Ross DG,
Diliberto JJ, Birnbaum LS. Relative potenicies of poly-
chlorinated dibenzo-p-dioxins, dibenzofurans, and
biphenyls derived from hepatic porphyrin accumulation
in mice. Toxicol Appl Pharmacol 138:98–109 (1996). 
43. van Birgelen AP, Van der Kolk J, Fase KM, Bol I, Poiger H,
Van den Berg M, Brouwer A. Toxic potency of 2,3,3’,4,4’,5-
hexachlorobiphenyl relative to and in combination with
2,3,7,8-tetrachlorodibenzo-p-dioxin in a subchronic feeding
study in the rat. Toxicol Appl Pharmacol 126:202–213 (1994). 
44. Morrissey RE, Harris MW, Diliberto JJ, Birnbaum LS.
Limited PCB antagonism of TCDD-induced malformations
in mice. Toxicol Lett 60:19–25 (1992).
Articles • Burgin et al.
1168 VOLUME 109 | NUMBER 11 | November 2001 • Environmental Health Perspectives